

Aradigm Corp (ARDM) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/AA2EF63734FEN.html

Date: January 2020

Pages: 36

Price: US\$ 125.00 (Single User License)

ID: AA2EF63734FEN

Abstracts

Aradigm Corp (ARDM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.



Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Aradigm Corp (Aradigm) is a specialty pharmaceutical company that develops and commercializes inhalation drugs for the prevention and treatment of severe respiratory diseases. The company's product pipeline includes Pulmaquin (ARD-3150) and Lipoquin (ARD-3100) for the treatment of non-cystic bronchiectasis (BE) and cystic fibrosis (CF); ARD-1100, liposomal ciprofloxacin for the treatment of inhalation tularemia, anthrax infections, Q fever and pneumonic plague and ARD-1600, for the prevention and treatment of respiratory and other diseases in tobacco smokers through smoking cessation. Its proprietary pulmonary drug delivery platform, AERx, is customized for the delivery of drugs to the target along with liposomal formulations. Aradigm is headquartered in Hayward, California, the US.

Aradigm Corp Key Recent Developments

Feb 15,2019: Aradigm announces plans for reorganization under Chapter 11 of the U.S. Bankruptcy Code

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential



customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.



Note: Some sections may be missing if data is unavailable for the company



Contents

SECTION 1 - ABOUT THE COMPANY

Aradigm Corp - Key Facts

Aradigm Corp - Key Employees

Aradigm Corp - Key Employee Biographies

Aradigm Corp - Major Products and Services

Aradigm Corp - History

Aradigm Corp - Company Statement

Aradigm Corp - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview

Aradigm Corp - Business Description

Aradigm Corp - Corporate Strategy

Aradigm Corp - SWOT Analysis

SWOT Analysis - Overview

Aradigm Corp - Strengths

Aradigm Corp - Weaknesses

Aradigm Corp - Opportunities

Aradigm Corp - Threats

Aradigm Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 - COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020



Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020 Aradigm Corp, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Feb 15, 2019: Aradigm announces plans for reorganization under Chapter 11 of the U.S. Bankruptcy Code

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer



List Of Tables

LIST OF TABLES

Aradigm Corp, Key Facts

Aradigm Corp, Key Employees

Aradigm Corp, Key Employee Biographies

Aradigm Corp, Major Products and Services

Aradigm Corp, History

Aradigm Corp, Subsidiaries

Aradigm Corp, Key Competitors

Aradigm Corp, Ratios based on current share price

Aradigm Corp, Annual Ratios

Aradigm Corp, Annual Ratios (Cont...1)

Aradigm Corp, Interim Ratios

Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020

Aradigm Corp, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios



List Of Figures

LIST OF FIGURES

Aradigm Corp, Performance Chart (2013 - 2017)

Aradigm Corp, Ratio Charts

Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

Aradigm Corp, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Non-Invasive Monitoring Systems Inc Gilead Sciences Inc Bayer HealthCare AG Axentis Pharma AG Novartis AG Aptalis Pharma US Inc Alexza Pharmaceuticals Inc



I would like to order

Product name: Aradigm Corp (ARDM) - Financial and Strategic SWOT Analysis Review

Product link: https://marketpublishers.com/r/AA2EF63734FEN.html

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/AA2EF63734FEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970